输尿管镜活检与上尿路尿路上皮癌最终病理分级的差异
该多中心回顾性研究分析了314例上尿路尿路上皮癌患者的输尿管镜活检与手术病理结果,发现活检临床高级别占61%,而最终病理高级别占79%;活检cT1+占21%,而最终病理pT2+占45%。活检临床高级别联合cT1+对肌层浸润的阳性预测值为86%,两者均缺失的阴性预测值为80%;活检临床低级别肿瘤中51%术后升级为高级别。
要点
- 活检临床高级别和cT1+是肌层浸润的独立预测因素。
- 活检临床低级别肿瘤有51%术后升级为高级别。
- 活检组织≤1mm时肌层浸润漏诊风险增加。
核心结论
- 活检临床高级别、cT1+及高龄是肌层浸润性上尿路尿路上皮癌的独立危险因素。
- 活检临床低级别肿瘤存在显著升级风险,尤其尿细胞学阳性时。
研究设计与样本
- 回顾性多中心研究,纳入2000至2016年3家机构314例接受输尿管镜活检后手术的上尿路尿路上皮癌患者。
主要发现
- 活检时61%为临床高级别,21%为cT1+;最终病理79%为高级别,45%为pT2+。
- 活检临床高级别且cT1+对肌层浸润的阳性预测值为86%,两者均无的阴性预测值为80%。
- 活检临床低级别病例中51%术后升级为高级别。
- 尿细胞学阳性与升级风险增加相关但无统计学显著性。
- 活检组织≤1mm时肌层浸润漏诊可能性增加。
临床怎么用
- 应综合活检分级、分期及患者年龄评估肌层浸润风险。
- 对活检低级别肿瘤需警惕升级可能,尤其尿细胞学阳性者。
- 建议进行更广泛的输尿管镜取样以提高活检预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the discordance between ureteroscopic biopsy and surgical pathology findings for grading and staging upper tract urothelial carcinoma. We also sought to establish preoperative predictors of aggressive tumors. MATERIALS AND METHODS: We retrospectively reviewed the records of 314 patients who underwent ureteroscopic biopsy followed by surgical management of upper tract urothelial carcinoma from 2000 to 2016 at a total of 3 institutions. Our primary outcomes were muscle invasive (pT2 or greater) disease at surgical pathology and upgrading of clinical low grade tumors to pathological high grade. RESULTS: At biopsy 61% of the patients had clinical high grade tumors and 21% had subepithelial connective tissue invasion (cT1+). On final pathology 79% of the patients had pathological high grade tumors and 45% had stage pT2 or greater. On multivariate analysis advanced patient age, clinical high grade and cT1+ were independently associated with pT2 or greater. The combined presence of clinical high grade and cT1+ had 86% positive predictive value for muscle invasion while the combined absence of clinical high grade and cT1+ had 80% negative predictive value. The likelihood of missing invasion on biopsy in patients with muscle invasive disease was increased when biopsy fragments were limited to 1 mm or less. Of clinical low grade cases on biopsy 51% were upgraded at surgery. The presence of positive urine cytology was associated with an increased risk of upgrading but this was not statistically significant. CONCLUSIONS: Clinical high grade, cT1+ on biopsy and advanced patient age are independent risk factors for muscle invasive upper tract urothelial carcinoma. There is a significant risk of upgrading in patients with clinical low grade tumors on biopsy, especially when urine cytology is positive. The predictive value of biopsy can likely be improved by more extensive ureteroscopic sampling.
引用
- Margolin EJ, Matulay JT, Li G, et al. Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma. J Urol. 2018. PMID: 29427584. doi:10.1016/j.juro.2018.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。